$748 Mln
$-29 Mln
--
As on 02-Oct-2023 16:00 EDT
$0.41
•
1.83%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| -1.90 | -4.13 | 5.91 | 42.07 | 1.63 | 8.80 | -- |
|
S&P BSE Sensex*
| 7.71 | 0.22 | 1.26 | 14.11 | 19.20 | 12.40 | 12.88 |
|
S&P BSE Healthcare#
| 23.72 | 2.78 | 10.39 | 22.09 | 12.74 | 13.60 | 11.62 |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| 24.20 | -6.74 | -2.67 | 19.86 | -6.95 | 18.56 | -43.38 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Healthcare
| -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 | -12.88 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Collegium Pharmaceutical Inc. (COLL) stood at $ 1,627 Mln as on 31-Mar-23
The share price of Collegium Pharmaceutical Inc. (COLL) is $22.760000 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Collegium Pharmaceutical Inc. (COLL) has given a return of 1.63% in the last 3 years.
Collegium Pharmaceutical Inc. (COLL) has a market capitalisation of $ 748 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Collegium Pharmaceutical Inc. (COLL) is 3.86 times as on 02-Jun-2023, a 0.37% premium to its peers’ median range of 2.82 times.
Since, TTM earnings of Collegium Pharmaceutical Inc. (COLL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Collegium Pharmaceutical Inc. (COLL) and enter the required number of quantities and click on buy to purchase the shares of Collegium Pharmaceutical Inc. (COLL).
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
The CEO & director of Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.. is Collegium Pharmaceutical Inc. (COLL), and CFO & Sr. VP is Mr. Joseph J. Ciaffoni.
The promoters of Collegium Pharmaceutical Inc. (COLL) have pledged 0% of the total equity as on Dec-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
11
|
|
|
10
|
|
|
1
|
|
|
0
|
| Collegium Pharmaceutical Inc. (COLL) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.58
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
3.42
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Collegium Pharmaceutical Inc. (COLL) was $-29 Mln.
$748.29 Mln
$524.95 Mln
$-29.36 Mln
$269.48 Mln
$806.24 Mln
High
$15.92 - 30.22
34,594,800
NASDAQ: COLL
Stoughton, MA
https://www.collegiumpharma.com
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe... enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
